Skip to main content

Market Overview

Adamis Pharma's Tempol Decreases COVID-19 Related Lung Inflammation In Animal Studies


Adamis Pharmaceuticals Corp (NASDAQ: ADMP) has reported positive data from lab studies conducted in animal models.

  • The study showed that Tempol-treated hamsters challenged with COVID-19 infection achieved decreased inflammation in the lungs compared to controls.
  • The group plans on submitting the publication to a peer-review journal.
  • Recently, the FDA cleared Adamis to proceed with a Phase 2/3 study to examine the effects of Tempol on preventing COVID-19 related hospitalization.
  • Price Action: ADMP shares are trading 9.6% higher at $1.14 in market trading hours on the last check Monday.

Related Articles (ADMP)

View Comments and Join the Discussion!

Posted-In: Covid-19 Phase 2 Clinical TrialBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at